Technical Analysis for ZGNX - Zogenix, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
![]() |
46.99 | -0.15% | -0.07 |
ZGNX closed down 0.15 percent on Friday, February 15, 2019, on 70 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Mar 5
ADX | Long-Term | Intermediate-Term | Short-Term |
---|---|---|---|
Strong | Up | Up | Up |
See historical ZGNX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Feb 15 | Outside Day | Range Expansion | 0.00% |
Feb 15 | Overbought Stochastic | Strength | 0.00% |
Feb 14 | Slingshot Bullish | Bullish Swing Setup | -0.15% |
Feb 14 | Overbought Stochastic | Strength | -0.15% |
Feb 13 | Shooting Star Candlestick | Bearish | -1.53% |
Feb 13 | Lizard Bearish | Bearish Day Trade Setup | -1.53% |
Feb 13 | Doji - Bearish? | Reversal | -1.53% |
Feb 13 | Overbought Stochastic | Strength | -1.53% |
Feb 13 | Upper Bollinger Band Touch | Strength | -1.53% |
Feb 12 | 180 Bullish Setup | Bullish Swing Setup | -0.97% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-05
- Sector: Healthcare
- Industry: Bio Medical Devices
Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company's lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.
Chemistry Pharmaceutical Pain Schizophrenia Central Nervous System Disorders Morphinans Neurochemistry Cell Signaling European Union Ketones Migraine Bipolar Disorder Hydrocodone Severe Chronic Pain Treatment Of Central Nervous System Disorders Treatment Of Migraine Indoles Retail Pharmacies Triptans
Chemistry Pharmaceutical Pain Schizophrenia Central Nervous System Disorders Morphinans Neurochemistry Cell Signaling European Union Ketones Migraine Bipolar Disorder Hydrocodone Severe Chronic Pain Treatment Of Central Nervous System Disorders Treatment Of Migraine Indoles Retail Pharmacies Triptans
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength | |||
Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. |
See more ZGNX news...
Indicators
Indicator | Value |
---|---|
52 Week High | 62.75 |
52 Week Low | 33.43 |
Average Volume | 510,638 |
200-Day Moving Average | 44.7805 |
50-Day Moving Average | 42.1138 |
20-Day Moving Average | 44.352 |
10-Day Moving Average | 46.69 |
Average True Range | 1.9164 |
ADX | 29.33 |
+DI | 26.1119 |
-DI | 12.3954 |
Chandelier Exit (Long, 3 ATRs ) | 43.1108 |
Chandelier Exit (Short, 3 ATRs ) | 46.0192 |
Upper Bollinger Band | 49.4609 |
Lower Bollinger Band | 39.2431 |
Percent B (%b) | 0.76 |
BandWidth | 23.037969 |
MACD Line | 1.5802 |
MACD Signal Line | 1.3556 |
MACD Histogram | 0.2246 |
Fundamentals | Value |
---|---|
Market Cap | 1.17 Billion |
Num Shares | 24.8 Million |
EPS | -3.42 |
Price-to-Earnings (P/E) Ratio | -13.74 |
Price-to-Sales | 35.07 |
Price-to-Book | 12.08 |
PEG Ratio | -0.43 |
Dividend | 0.00 |
Dividend Yield | 0.00% |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 49.62 | ||||
Resistance 3 (R3) | 49.70 | 48.91 | 49.18 | ||
Resistance 2 (R2) | 48.91 | 48.24 | 48.87 | 49.03 | |
Resistance 1 (R1) | 47.95 | 47.83 | 47.56 | 47.87 | 48.89 |
Pivot Point | 47.16 | 47.16 | 46.96 | 47.12 | 47.16 |
Support 1 (S1) | 46.20 | 46.49 | 45.81 | 46.12 | 45.09 |
Support 2 (S2) | 45.41 | 46.08 | 45.37 | 44.95 | |
Support 3 (S3) | 44.45 | 45.41 | 44.80 | ||
Support 4 (S4) | 44.37 |